The Odisha market grew the highest followed by Punjab and Vidarbha
The Indian Pharma Market (IPM) clocked Rs 8139 crores in February 2016 and has grown at 12 per cent. Amongst the top 10 corporates, Mankind grew by 27.7 per cent, Sun Pharma by 19.3 per cent and Lupin at 18.6 per cent.
In February 2016, amongst the top 10, Mankind Pharma grew by 27.7 per cent, Sun by 19.3 per cent and Lupin at 18.6 per cent. 16 corporates have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Bharat Serums has the highest growth of 36.3 per cent followed by DRL at 32.5 per cent and Mankind at 27.7 per cent. 23 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, DRL has the highest growth of 32.5 per cent followed by Intas at 22.5 per cent and USV at 20.1 per cent. Amongst the 21-30 ranked corporates, Novartis has the highest growth at 16.7 per cent followed by Ipca at 11.5 per cent and Eris at 10.1 per cent. Amongst the 31-40 ranked corporates, Bharat Serums grew at 36.3 per cent followed by JBCPL at 18.7 per cent and Hetero at 11.8 per cent. Amongst the 41-50 ranked corporates, Systopic has the highest growth at 25.8 per cent followed by Panacea at 13.8 per cent and Wallace at 13 per cent.
Amongst the 51-60 ranked corporates, Boehringer Ingelheim grew at 57.1 per cent followed by Fresenius Kabi at 32.2 per cent and Corona at 16.3 per cent. Amongst the 61-70 ranked corporates, RPG grew at 25.4 per cent followed by Shreya, which grew at 23.8 per cent and Geno at 19. Amongst the 71-80 ranked corporates, Samarth grew at 44.3 per cent followed by Lincoln at 29.7 per cent and Walter Bushnell at 23.2 per cent. Amongst the 81-90 ranked corporates, Galpha grew at 48.7 per cent followed by Veritaz grew at 37.5 per cent followed by Dabur at 37.2 per cent. Amongst the 91-100 ranked corporates, Gland grew at 34.9 per cent followed by Serum Institute at 20.3 per cent and Jenburkt at 18.8 per cent. The 100th biggest corporate is overseas and 150th biggest corporate is UTH in the IPM.
Boehringer Ingelheim entered the Rs 300-crore club, Samarth Life Sciences the Rs 150-crore club, on MAT Basis. Innovcare a new company made its presence felt at 213th rank with a turnover of Rs 12 crores.
Indian companies have grown at 14 per cent versus five per cent for MNCs in February 2016. Amongst the top 50 in MNCs, Novartis grew at 16.7 per cent followed by Merck at 11.5 per cent and Janssen at 9.6 per cent. Under the Non-NLEM category, Indian companies grew at 12.4 per cent whereas MNCs grew at 1.1 per cent.
The NLEM containing molecules market grew at 6.9 per cent whereas the non DPCO market grew by 12.9 per cent and Non -Sch Para 19 Market at 15.3 per cent resulting in an overall growth of 12 per cent for February 2016. The NLEM and Non-NLEM Category showed unit growth a 3.4 per cent and 3.3 per cent respectively. The Non-Sch Para 19 Market grew at 9.1 per cent from units perspective.
14 therapies have outgrown the IPM growth. The respiratory market grew at 5.8 per cent, gastrointestinal market grew at 16.4 per cent, pain and analgesics market grew at 9.7 per cent whereas the anti-infectives grew at 5.3 per cent. The anti-diabetic market grew at 18.1 per cent and cardiac at 17.3 per cent in chronic business. The derma market grew by 16.8 per cent, urology at 17 per cent and neuro/ CNS at 18.9 per cent.
14 regions have outgrown the IPM growth. The Odisha market grew the highest at 22.2 per cent followed by Punjab at 20.8 per cent and Vidarbha market at 18.5 per cent. No regions had negative growth in February 2016.
Amoxycillin + Clavulanic Acid market grew at 2.8 per cent and Glimepiride + Metformin Market grew at 19.3 per cent. The markets of paracetamol grew at 14.4 per cent, Atorvastatin 11.7 per cent, Probiotic Microbes at 39.7 per cent, Cefixime -4.8 per cent, Pantoprazole 17.6 per cent, Montelukast + Levocetrizine at 7.0 per cent, Glimepiride + Metformin + Pioglitazone at 19.1 per cent, Vitamin-D at 22.0 per cent, Hydroquinone + Mometasone + Tretinoin at 12.8 per cent, Voglibose + Metformin + Glimepiride at 46.9 per cent, Rosuvastatin at 22.8 per cent, Protein Supplements at 6.9 per cent, Azithromycin at -6.4 per cent, Calcium Carbonate + Vit D3 market at -0.1 per cent, Paracetamol + Phenylephrine + Chlorpheniramine at -4.6 per cent, Meropenem at 48.3 per cent, Montelukast + Fexofenadine at 22.6 per cent, Diclofenac at 21.5 per cent. The 50th biggest market was Voglibose + Metformin + Glimepiride and 100th biggest market is Levofloxacin.
Mixtard lead the pack with Rs 36 crores followed by Glycomet GP & Augmentin at Rs 28 crores. On MAT basis, Glycomet GP is ranked now at number two.
A few brands who have gained ranks include Unwanted Kit (+75), Meronem (+54), Electral Powder (+51), Aciloc RD (+32), Betnovate C (+29), Rabipur (+27), Mifegest Kit (+25), Voveran, Omez (+22), Telma (+21), Rosuvas, Vertin, Trajenta (+20), Thyronorm, Betnovate N, Rotarix, Aztor, Deriphylin (+18), Istamet (+17), Storvas (+16), Galvus Met, Jalra M, Levipil, Eltroxin, Atorva, Pantocid D SR, Cardace (+15), Gluconorm G (+14), Gemer, Susten, Duphalac (+13), Ultracet (+12), Pan, Synflorix, Budecort, Glycomet, Mucaine (+11), Rantac (+9), Orofer XT (+8), amongst top 100 brands over February 2015. Lonopin, Razo D, Brilinta, Zerodol P, Enterogermina, Econorm, Zerodol P, Finecef, Metpure XL, Omez D are few brands which have gained ranks in 101-200 ranked brands.
A few brands that have moved up ranks fastest into Top 300 brands for the month of February – 16 are Revital H, Lonopin, Ocid, Similac, Candiforce, Razo D, Glimestar M, Brilinta, Gabapin NT. The 300th biggest brand was Reditux from DRL. A total of 224 brands and 409 SKUs were launched in February 2016. The top new brands were Pegclear, Azacytin, Epilyno.
One brand was launched in Sofosbuvir + Ledipasavir category – Sofocruz LP from Torrent. Within the VMS category, AIOCD sees GB 29 Total (Corona), Maxical Plus (Mankind) & Ensame (Icarus Healthcare), within anti-diabetic, Glytrin (Medley), Glimipack M, Voglipack ( Koye), within respiratory, Acemont (Avis Life Care), Ranmotel C (Sun), Vitaresp AB (Alembic), within Anti – Infectives we see Tygaray ( Mylan), Sofocruz LP (Torrent) & Kartel (Saffron), within cardiac, Modlip D (Torrent), Benipack (Koye) & Supertel (Gland) and in gastro intestinal, Pegclear (Zuventus), Eco All Z (Hetero) & Glinzo D SR (Glenmark). The biggest new launch by a MNC was Tygaray in February 2016.
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com/